Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population.
A range of therapies are used to treat AML; however, the market is dominated by the use of agents that induce DNA damage. As drug treatments and clinical trial designs continue to evolve, novel agents with new mechanisms of action are set to enter this market.
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Three key opinion leaders from the United States and five from Europe with expertise in AML treatment were interviewed for this report.
Epidemiology: Diagnosed incident cases of AML (excluding APL) and APL in the United States and EU5.
Population segments in market forecast: First-line AML (excluding APL), relapsed/refractory AML (excluding APL), first-line APL, relapsed/refractory APL.
Emerging therapies: Phase I/II: 4 drugs; Phase III: 8 drugs.